Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALLO NASDAQ:PRAX NASDAQ:QURE NASDAQ:SPRY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.13-3.4%$1.19$0.86▼$3.78$250.72M0.364.28 million shs1.59 million shsPRAXPraxis Precision Medicines$37.71-4.3%$49.09$26.70▼$91.83$793.80M2.61450,517 shs496,513 shsQUREuniQure$16.49-2.7%$15.24$4.45▼$19.18$904.76M0.141.34 million shs670,611 shsSPRYARS Pharmaceuticals$10.03-1.2%$15.40$9.79▼$18.90$991.27M0.871.72 million shs2.27 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics+5.41%+5.41%+13.59%-12.69%-59.79%PRAXPraxis Precision Medicines-2.01%-14.47%-18.65%-11.02%-31.96%QUREuniQure-3.09%-4.46%+18.46%+10.43%+209.69%SPRYARS Pharmaceuticals-3.33%-5.05%-39.08%-34.05%-15.42%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALLOAllogene Therapeutics$1.13-3.4%$1.19$0.86▼$3.78$250.72M0.364.28 million shs1.59 million shsPRAXPraxis Precision Medicines$37.71-4.3%$49.09$26.70▼$91.83$793.80M2.61450,517 shs496,513 shsQUREuniQure$16.49-2.7%$15.24$4.45▼$19.18$904.76M0.141.34 million shs670,611 shsSPRYARS Pharmaceuticals$10.03-1.2%$15.40$9.79▼$18.90$991.27M0.871.72 million shs2.27 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALLOAllogene Therapeutics+5.41%+5.41%+13.59%-12.69%-59.79%PRAXPraxis Precision Medicines-2.01%-14.47%-18.65%-11.02%-31.96%QUREuniQure-3.09%-4.46%+18.46%+10.43%+209.69%SPRYARS Pharmaceuticals-3.33%-5.05%-39.08%-34.05%-15.42%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALLOAllogene Therapeutics 2.75Moderate Buy$8.44647.30% UpsidePRAXPraxis Precision Medicines 2.90Moderate Buy$85.88127.72% UpsideQUREuniQure 3.00Buy$37.45127.13% UpsideSPRYARS Pharmaceuticals 3.14Buy$32.50224.03% UpsideCurrent Analyst Ratings BreakdownLatest ALLO, SPRY, PRAX, and QURE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/8/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.009/5/2025QUREuniQureHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$70.009/4/2025SPRYARS PharmaceuticalsRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.009/3/2025PRAXPraxis Precision MedicinesLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/2/2025PRAXPraxis Precision MedicinesJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/29/2025QUREuniQureChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$35.008/14/2025QUREuniQureMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeNeutral ➝ Outperform$30.008/5/2025PRAXPraxis Precision MedicinesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$105.00 ➝ $115.008/4/2025ALLOAllogene TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Perform8/4/2025ALLOAllogene TherapeuticsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Neutral7/30/2025QUREuniQureCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$47.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALLOAllogene Therapeutics$20K12,536.22N/AN/A$2.01 per share0.56PRAXPraxis Precision Medicines$8.55M92.84N/AN/A$23.90 per share1.58QUREuniQure$14.34M63.11N/AN/A($0.14) per share-117.79SPRYARS Pharmaceuticals$89.15M11.12$0.01 per share1,239.92$2.64 per share3.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALLOAllogene Therapeutics-$257.59M-$1.11N/AN/AN/AN/A-55.99%-42.75%11/6/2025 (Estimated)PRAXPraxis Precision Medicines-$182.82M-$12.29N/AN/AN/A-2,137.48%-60.07%-54.84%11/5/2025 (Estimated)QUREuniQure-$239.56M-$3.92N/AN/AN/A-1,387.98%-1,010.74%-33.27%11/4/2025 (Estimated)SPRYARS Pharmaceuticals$8M-$0.49N/AN/AN/A-42.74%-21.85%-15.88%11/12/2025 (Estimated)Latest ALLO, SPRY, PRAX, and QURE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025ALLOAllogene Therapeutics-$0.28-$0.23+$0.05-$0.23N/AN/A8/13/2025Q2 2025SPRYARS Pharmaceuticals-$0.41-$0.46-$0.05-$0.46$12.92 million$15.72 million8/4/2025Q2 2025 & Study ResultPRAXPraxis Precision Medicines-$3.40-$3.31+$0.09-$3.31$0.15 millionN/A7/29/2025Q2 2025QUREuniQure-$0.89-$0.69+$0.20-$0.69$5.00 million$5.26 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALLOAllogene TherapeuticsN/AN/AN/AN/AN/APRAXPraxis Precision MedicinesN/AN/AN/AN/AN/AQUREuniQureN/AN/AN/AN/AN/ASPRYARS PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALLOAllogene TherapeuticsN/A8.928.92PRAXPraxis Precision MedicinesN/A6.316.31QUREuniQure1.539.989.98SPRYARS Pharmaceuticals0.376.175.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALLOAllogene Therapeutics83.63%PRAXPraxis Precision Medicines67.84%QUREuniQure78.83%SPRYARS Pharmaceuticals68.16%Insider OwnershipCompanyInsider OwnershipALLOAllogene Therapeutics13.20%PRAXPraxis Precision Medicines2.70%QUREuniQure4.79%SPRYARS Pharmaceuticals33.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALLOAllogene Therapeutics310221.88 million192.59 millionOptionablePRAXPraxis Precision Medicines11021.05 million20.48 millionOptionableQUREuniQure50054.87 million52.24 millionOptionableSPRYARS Pharmaceuticals9098.83 million65.72 millionOptionableALLO, SPRY, PRAX, and QURE HeadlinesRecent News About These CompaniesOctagon Capital Advisors LP Buys Shares of 625,000 ARS Pharmaceuticals, Inc. $SPRYSeptember 11 at 6:03 AM | marketbeat.comARS Pharmaceuticals announces real-world evidence on neffy effectivenessSeptember 9 at 5:25 PM | finance.yahoo.comAlliancebernstein L.P. Has $49.35 Million Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 9 at 4:56 AM | marketbeat.comWhat is Roth Capital's Estimate for SPRY Q3 Earnings?September 9 at 2:10 AM | marketbeat.comWhat is Roth Capital's Forecast for SPRY Q3 Earnings?September 9 at 2:03 AM | americanbankingnews.comReal-World Evidence Supports Clinical Effectiveness of neffy® (epinephrine nasal spray) in Patients Experiencing AnaphylaxisSeptember 8, 2025 | globenewswire.comAlyeska Investment Group L.P. Cuts Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 8, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Sets New 52-Week Low - Should You Sell?September 8, 2025 | marketbeat.comTrexquant Investment LP Buys 44,206 Shares of ARS Pharmaceuticals, Inc. $SPRYSeptember 8, 2025 | marketbeat.comARS Pharmaceuticals (NASDAQ:SPRY) Reaches New 12-Month Low - What's Next?September 8, 2025 | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Now Covered by Analysts at Roth CapitalSeptember 7, 2025 | americanbankingnews.comARS Pharmaceuticals (NASDAQ:SPRY) Coverage Initiated at Roth CapitalSeptember 6, 2025 | marketbeat.comARS Pharmaceuticals, Inc. $SPRY Shares Purchased by Cormorant Asset Management LPSeptember 6, 2025 | marketbeat.comArdsley Advisory Partners LP Takes $4.09 Million Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 5, 2025 | marketbeat.comRoth Capital Initiates Coverage of ARS Pharmaceuticals (SPRY) with Buy RecommendationSeptember 5, 2025 | msn.comARS Pharmaceuticals (SPRY) Faces Patent Test as Lupin Files ANDASeptember 4, 2025 | msn.comARS Pharmaceuticals initiated with a Buy at Roth CapitalSeptember 4, 2025 | msn.comMPM Bioimpact LLC Acquires New Shares in ARS Pharmaceuticals, Inc. $SPRYSeptember 4, 2025 | marketbeat.comQuarry LP Takes $415,000 Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 3, 2025 | marketbeat.comRafferty Asset Management LLC Lowers Stock Position in ARS Pharmaceuticals, Inc. $SPRYSeptember 3, 2025 | marketbeat.comWellington Management Group LLP Sells 31,476 Shares of ARS Pharmaceuticals, Inc. $SPRYSeptember 2, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Kratos Keeps Climbing After Q2, But Valuation Risk LoomsBy Leo Miller | August 18, 2025Oracle Has Spoken: AI Changes EverythingBy Thomas Hughes | September 10, 2025ALLO, SPRY, PRAX, and QURE Company DescriptionsAllogene Therapeutics NASDAQ:ALLO$1.13 -0.04 (-3.42%) Closing price 04:00 PM EasternExtended Trading$1.13 0.00 (0.00%) As of 04:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.Praxis Precision Medicines NASDAQ:PRAX$37.71 -1.71 (-4.34%) Closing price 04:00 PM EasternExtended Trading$37.74 +0.03 (+0.09%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.uniQure NASDAQ:QURE$16.49 -0.45 (-2.66%) Closing price 04:00 PM EasternExtended Trading$16.74 +0.26 (+1.55%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.ARS Pharmaceuticals NASDAQ:SPRY$10.03 -0.12 (-1.18%) Closing price 04:00 PM EasternExtended Trading$9.98 -0.04 (-0.45%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Why Micron Stock Could Outperform NVIDIA in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
